ArticleJournal of endocrinological investigation2026
Therapeutic errors associated with thyroid medications in non-healthcare facility settings reported to United States poison centers, 2000-2024.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo investigate the characteristics and trends of therapeutic errors involving thyroid medications in non-healthcare facility settings reported to United States (US) poison centers.
methodsNational Poison Data System data from 2000 to 2024 were retrospectively analyzed and population-based rates were calculated.
resultsThere were 89,614 reported thyroid medication therapeutic error-related exposures in non-healthcare facility settings from 2000 to 2024, including medications used to treat hypothyroidism (n = 85,030, 95%) and hyperthyroidism (n = 4,584, 5%). Most (97%) exposures did not receive healthcare facility treatment. The annual rate per 100,000 US population of therapeutic errors increased by 263% from 0.51 in 2000 to 1.85 in 2024. Females accounted for more than two-thirds of exposures, as did adults 40 years and older. Therapeutic errors involving liothyronine were more likely to be associated with a medical admission (OR: 5.15, 95% CI: 2.80-9.48) or a moderate or major effect (OR: 10.53, 95% CI: 7.27-15.27) than those involving other medications used to treat hypothyroidism. Compared with therapeutic errors involving acute or acute-on-chronic exposures, chronic exposures were more likely to be associated with a medical admission (OR: 6.28, 95% CI: 4.24-9.28) or a moderate or major effect (OR: 15.33, 95% CI: 12.00-19.59) for medications used to treat hypothyroidism, and similarly, a medical admission (OR: 8.84, 95% CI: 1.09-71.71) or a moderate or major effect (OR: 15.37, 95% CI: 4.28-55.21) for medications used to treat hyperthyroidism.
conclusionTherapeutic errors involving thyroid medications have been increasing, although most clinical outcomes are not severe. Increased prevention efforts should be considered for higher-risk subgroups.
Indexed as
Identifiers
42905304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.